The key to 15% enhancement of 5-year survival for liver cancer for the plan of “Health-China 2030”_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 WEN Tianfu , LI Chuan , ZHANG Xiaoyun , PENG Wei , SHEN Junyi

Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

WEN Tianfu, Email: wentianfu@scu.edu.cn

Keywords：

liver cancer; conversion to resectability; screening; HBV infection; MDT

DOI：

10.7507/1007-9424.202308033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

To challenge the 15% enhancement of 5-year survival of cancer for the plan of “Health-China 2030”, we must strive the following measurements to complete the 15% enhancement of 5-year survival of liver cancer: conduct conversion therapy and conversion to resectability for the 70% of unresectable intermediate-to-advanced stage liver cancer so as to prolong survival; try our best to identify and treat the people of HBV and HCV infection, and to screen the risk people so as to reduce the incidence of liver cancer and the proportion for intermediate-to-advanced stage liver cancer; continue to try our best in the full course management of liver cancer under the frame of MDT.

Citation： WEN Tianfu, LI Chuan, ZHANG Xiaoyun, PENG Wei, SHEN Junyi. The key to 15% enhancement of 5-year survival for liver cancer for the plan of “Health-China 2030”. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(11): 1281-1283. doi: 10.7507/1007-9424.202308033 Copy

1.	Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	International Agency for Research on Cancer. Data visualization tools for exploring the global cancer burden in 2020. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.
4.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
5.	《“健康中國2030”規劃綱要》 (附全文). https://www.sohu.com/a/275717094_727248.
6.	Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival. Surgery, 1970, 68(2): 383-388.
7.	Yu YQ, Tang ZY, Zhou XD, et al. Treatment of huge primary liver cancer in stages. Chin J Surg, 1983, 21: 92-93.
8.	Chen H, Wu MC. Reoperative primary liver cancer. Report of 28 cases. Chin Med J (Engl), 1987, 100(10): 795-799.
9.	Sitzmann JV, Order SE, Klein JL, et al. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol, 1987, 5(10): 1566-1573.
10.	Tang ZY, Yu YQ, Ma ZC, et al. Conversion of surgically verified unresectable to resectable hepatocellular carcinoma-a report of 26 patients with subsequent resection. Chinese J Cancer Res, 1989, 1: 41-47.
11.	Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg, 2004, 240(2): 299-305.
12.	文天夫. 轉化切除是提高肝細胞癌切除率的重要途徑. 中國普外基礎與臨床雜志, 2020, 27(2): 133-136.
13.	He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
14.	Zhang XY, Zhu XR, Li C. The safety and efficacy of TACE+lenvatinib+PD-1 antibody of advanced unresectable HCC. 2022 ASCO-GI, poster session 45, San Francisco, California, United States.
15.	張曉赟, 朱心睿, 彭偉, 等. 經肝動脈化療栓塞+侖伐替尼+PD-1單抗在中晚期不可切除肝癌轉化切除中的安全性和有效性的前瞻性隊列研究: 初步報告. 中國普外基礎與臨床雜志, 2022, 29(1): 39-45.
16.	Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma, 2021, 8: 1233-1240.
17.	Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther, 2023, 8(1): 58. doi: 10.1038/s41392-022-01235-0.
18.	Peng W, Zhang X, Li C, et al. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. Br J Surg, 2023, 110(7): 746-748.
19.	Zhang XY, Zhu X, Feng X, et al. The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study. Ann Oncol, 2022, 33: Issue S7-s870-715p.
20.	張曉赟, 朱心睿, 彭偉等. 侖伐替尼+經肝動脈化療栓塞+PD-1單抗治療肝細胞癌合并門靜脈主干癌栓和海綿樣變 (4例報道). 中國普外基礎與臨床雜志, 2022, 29(5): 618-622.
21.	中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019年版). 中國實用外科雜志, 2020, 40(2): 121-138.
22.	中華醫學會肝病學分會, 中華醫學會感染病學分會. 慢性乙型肝炎防治指南 (2022年版). 中華肝臟病雜志, 2022, 30(12): 1309-1331.
23.	四川大學華西醫院肝癌MDT團隊. 肝細胞癌切除術后復發轉移的防治: 華西醫院多學科專家共識. 中國普外基礎與臨床雜志, 2017, 24(8): 927-939.
24.	Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
25.	樊嘉. 我國肝癌診療和臨床研究進展. 中國實用外科雜志, 2019, 39(10): 1010-1014.

1. Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. International Agency for Research on Cancer. Data visualization tools for exploring the global cancer burden in 2020. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.
4. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
5. 《“健康中國2030”規劃綱要》 (附全文). https://www.sohu.com/a/275717094_727248.
6. Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival. Surgery, 1970, 68(2): 383-388.
7. Yu YQ, Tang ZY, Zhou XD, et al. Treatment of huge primary liver cancer in stages. Chin J Surg, 1983, 21: 92-93.
8. Chen H, Wu MC. Reoperative primary liver cancer. Report of 28 cases. Chin Med J (Engl), 1987, 100(10): 795-799.
9. Sitzmann JV, Order SE, Klein JL, et al. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol, 1987, 5(10): 1566-1573.
10. Tang ZY, Yu YQ, Ma ZC, et al. Conversion of surgically verified unresectable to resectable hepatocellular carcinoma-a report of 26 patients with subsequent resection. Chinese J Cancer Res, 1989, 1: 41-47.
11. Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg, 2004, 240(2): 299-305.
12. 文天夫. 轉化切除是提高肝細胞癌切除率的重要途徑. 中國普外基礎與臨床雜志, 2020, 27(2): 133-136.
13. He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
14. Zhang XY, Zhu XR, Li C. The safety and efficacy of TACE+lenvatinib+PD-1 antibody of advanced unresectable HCC. 2022 ASCO-GI, poster session 45, San Francisco, California, United States.
15. 張曉赟, 朱心睿, 彭偉, 等. 經肝動脈化療栓塞+侖伐替尼+PD-1單抗在中晚期不可切除肝癌轉化切除中的安全性和有效性的前瞻性隊列研究: 初步報告. 中國普外基礎與臨床雜志, 2022, 29(1): 39-45.
16. Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma, 2021, 8: 1233-1240.
17. Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther, 2023, 8(1): 58. doi: 10.1038/s41392-022-01235-0.
18. Peng W, Zhang X, Li C, et al. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. Br J Surg, 2023, 110(7): 746-748.
19. Zhang XY, Zhu X, Feng X, et al. The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study. Ann Oncol, 2022, 33: Issue S7-s870-715p.
20. 張曉赟, 朱心睿, 彭偉等. 侖伐替尼+經肝動脈化療栓塞+PD-1單抗治療肝細胞癌合并門靜脈主干癌栓和海綿樣變 (4例報道). 中國普外基礎與臨床雜志, 2022, 29(5): 618-622.
21. 中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019年版). 中國實用外科雜志, 2020, 40(2): 121-138.
22. 中華醫學會肝病學分會, 中華醫學會感染病學分會. 慢性乙型肝炎防治指南 (2022年版). 中華肝臟病雜志, 2022, 30(12): 1309-1331.
23. 四川大學華西醫院肝癌MDT團隊. 肝細胞癌切除術后復發轉移的防治: 華西醫院多學科專家共識. 中國普外基礎與臨床雜志, 2017, 24(8): 927-939.
24. Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
25. 樊嘉. 我國肝癌診療和臨床研究進展. 中國實用外科雜志, 2019, 39(10): 1010-1014.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The key to 15% enhancement of 5-year survival for liver cancer for the plan of “Health-China 2030”

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content